Source:http://linkedlifedata.com/resource/pubmed/id/21273080
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
2011-2-14
|
pubmed:abstractText |
Leu-enkephalin is an endogenous pain modulating opioid pentapeptide. Its development as a potential pharmaceutic has been hampered by poor membrane permeability and susceptibility to enzymatic degradation. The addition of an unnatural amino acid containing a lipidic side chain at the N-terminus and the modification of the C-terminus to a carboxyamide was performed to enhance the nasal delivery of the peptide. Two lipidic derivatives with varying side chain lengths (C(8)-Enk-NH(2) (1), C(12)-Enk-NH(2) (2)) and their acetylated analogues were successfully synthesised. Caco-2 cell monolayer permeability and Caco-2 cell homogenate stability assays were performed. C(8)-Enk-NH(2) (1) and its acetylated analogue Ac-C8-Enk-NH(2) (3) exhibited apparent permeabilities (mean±SD) of 2.51±0.75×10(-6)cm/s and 1.06±0.62×10(-6), respectively. C12-Enk-NH(2) (2) exhibited an apparent permeability of 2.43±1.26×10(-6) cm/s while Ac-C12-Enk-NH(2) (4) was not permeable through the Caco-2 monolayers due to its poor solubility. All analogues exhibited improved Caco-2 homogenate stability compared to Leu-Enk-NH(2) with t(½) values of: C8-Enk-NH(2) (1): 31.7 min, C(12)-Enk-NH(2) (2): 14.7 min, Ac-C8-Enk-NH(2) (3): 83 min, Ac-C(12)-Enk-NH(2) (4): 27 min. However, plasma stability assays revealed that the diastereoisomers of C8-Enk-NH(2) (1) did not degrade at the same rate, with the l isomer (t(1/2)=8.9 min) degrading into Leu-enkephalinamide and then des-Tyr-Leu-Enk-NH(2), whereas the d isomer was stable (t(1/2)=120 min). In vivo nasal administration of C(8)-Enk-NH(2) to male rats resulted in concentrations of 5.9±1.84×10(-2) ?M in the olfactory bulbs, 1.35±1.01×10(-2) ?M in the brain and 6.53±1.87×10(-3) ?M in the blood 10 min after administration.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
1464-3391
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright © 2011 Elsevier Ltd. All rights reserved.
|
pubmed:issnType |
Electronic
|
pubmed:day |
15
|
pubmed:volume |
19
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1528-34
|
pubmed:meshHeading |
pubmed-meshheading:21273080-Animals,
pubmed-meshheading:21273080-Caco-2 Cells,
pubmed-meshheading:21273080-Cell Membrane Permeability,
pubmed-meshheading:21273080-Enkephalin, Leucine,
pubmed-meshheading:21273080-Humans,
pubmed-meshheading:21273080-Hydrophobic and Hydrophilic Interactions,
pubmed-meshheading:21273080-Lipids,
pubmed-meshheading:21273080-Male,
pubmed-meshheading:21273080-Molecular Structure,
pubmed-meshheading:21273080-Nasal Mucosa,
pubmed-meshheading:21273080-Rats,
pubmed-meshheading:21273080-Rats, Sprague-Dawley
|
pubmed:year |
2011
|
pubmed:articleTitle |
Lipophilic derivatives of leu-enkephalinamide: in vitro permeability, stability and in vivo nasal delivery.
|
pubmed:affiliation |
School of Chemistry and Molecular Biosciences, University of Queensland, St. Lucia, Brisbane 4072, Australia.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|